Skip to main content

Generex Biotechnology Value Stock - Dividend - Research Selection

Generex Biotechnology

ISIN: US3714851033, WKN: 922012

Market price date: 15.01.2021
Market price: 0,29 USD

Generex Biotechnology Fundamental data and company key figures of the share

Annual reports in USD
Key figures 21-11-2020
Cash flow
Net operating cash flow -6.121.260
Capital Expenditures -4.616
Free cash flow -6.125.876
Balance sheet
Total Equity -21.456.000
Liabilities & Shareholders equity 45.382.900
Income statement
Net income -33.335.000
Eps (diluted) -0,460
Diluted shares outstanding 74.417.600
Net sales/revenue 2.661.400

Fundamental ratios calculated on: 15-01-2021

Key figures 15-01-2021
Cash flow
P/C -3,77
P/FC -3,77
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization23.069.456,00 USD
CountryUnited States
Raw Data SourceUS GAAP in Millionen USD
Stock Split2020-02-25,7.000000/5.000000; 2020-01-13,7.000000/5.000000; 2019-12-02,2.000000/1.000000; 2019-10-31,2.000000/1.000000; 2019-10-30,2.000000/1.000000; 2019-07-23,2.000000/1.000000; 2018-12-04,21.0000/1.0000; 2018-12-03,1.0000/21.0000; 2017-03-14,1.0000/1000.0000

Description of the company

Corporate History and Structure


We were incorporated in Delaware in September 1997 for the purpose of acquiring Generex Pharmaceuticals Inc., a Canadian corporation formed in November 1995 to engage in pharmaceutical and biotechnological research and development and other activities. Our acquisition of Generex Pharmaceuticals was completed in October 1997 in a transaction in which the holders of all outstanding shares of Generex Pharmaceuticals exchanged their shares for shares of our common stock.


In January 1998, we participated in a "reverse acquisition" with Green Mt. P. S., Inc., an inactive Idaho corporation formed in 1983. As a result of this transaction, our shareholders (the former shareholders of Generex Pharmaceuticals) acquired a majority (approximately 90%) of the outstanding capital stock of Green Mt., we became a wholly-owned subsidiary of Green Mt., Green Mt. changed its corporate name to Generex Biotechnology Corporation ("Generex Idaho"), and we changed our corporate name to GB Delaware, Inc. Because the reverse acquisition resulted in our shareholders becoming the majority holders of Generex Idaho, we were treated as the acquiring corporation in the transaction for accounting purposes. Thus, our historical financial statements, which essentially represented the historical financial statements of Generex Pharmaceuticals, were deemed to be the historical financial statements of Generex Idaho. In April 1999, we completed a reorganization in which we merged with Generex Idaho. In this transaction, all outstanding shares of Generex Idaho were converted into our shares, Generex Idaho ceased to exist as a separate entity, and we changed our corporate name back to "Generex Biotechnology Corporation." This reorganization did not result in any material change in our historical financial statements or current financial reporting.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,